Literature DB >> 23381789

Neprilysin regulates pulmonary artery smooth muscle cell phenotype through a platelet-derived growth factor receptor-dependent mechanism.

Vijaya Karoor1, Masahiko Oka, Sandra J Walchak, Louis B Hersh, York E Miller, Edward C Dempsey.   

Abstract

Reduced neprilysin (NEP), a cell surface metallopeptidase, which cleaves and inactivates proinflammatory and vasoactive peptides, predisposes the lung vasculature to exaggerated remodeling in response to hypoxia. We hypothesize that loss of NEP in pulmonary artery smooth muscle cells results in increased migration and proliferation. Pulmonary artery smooth muscle cells isolated from NEP(-/-) mice exhibited enhanced migration and proliferation in response to serum and platelet-derived growth factor, which was attenuated by NEP replacement. Inhibition of NEP by overexpression of a peptidase dead mutant or knockdown by small interfering RNA in NEP(+/+) cells increased migration and proliferation. Loss of NEP led to an increase in Src kinase activity and phosphorylation of PTEN, resulting in activation of the platelet-derived growth factor receptor (PDGFR). Knockdown of Src kinase with small interfering RNA or inhibition with PP2, a src kinase inhibitor, decreased PDGFR(Y751) phosphorylation and attenuated migration and proliferation in NEP(-/-) smooth muscle cells. NEP substrates, endothelin 1 or fibroblast growth factor 2, increased activation of Src and PDGFR in NEP(+/+) cells, which was decreased by an endothelin A receptor antagonist, neutralizing antibody to fibroblast growth factor 2 and Src inhibitor. Similar to the observations in pulmonary artery smooth muscle cells, levels of phosphorylated PDGFR, Src, and PTEN were elevated in NEP(-/-) lungs. Endothelin A receptor antagonist also attenuated the enhanced responses in NEP(-/-) pulmonary artery smooth muscle cells and lungs. Taken together our results suggest a novel mechanism for the regulation of PDGFR signaling by NEP substrates involving Src and PTEN. Strategies that increase lung NEP activity/expression or target key downstream effectors, like Src, PTEN, or PDGFR, may be of therapeutic benefit in pulmonary vascular disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23381789      PMCID: PMC3667616          DOI: 10.1161/HYPERTENSIONAHA.111.199588

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  28 in total

1.  The control of microvascular permeability and blood pressure by neutral endopeptidase.

Authors:  B Lu; M Figini; C Emanueli; P Geppetti; E F Grady; N P Gerard; J Ansell; D G Payan; C Gerard; N Bunnett
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

Review 2.  Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways.

Authors:  J T Parsons; S J Parsons
Journal:  Curr Opin Cell Biol       Date:  1997-04       Impact factor: 8.382

3.  Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension.

Authors:  Wai K P Wong; James A Knowles; Jane H Morse
Journal:  Am J Respir Cell Mol Biol       Date:  2005-07-07       Impact factor: 6.914

Review 4.  Neuroendocrine activation as a target of modern chronic heart failure pharmacotherapy.

Authors:  Łukasz Dobrek; Piotr Thor
Journal:  Acta Pol Pharm       Date:  2011 May-Jun       Impact factor: 0.330

5.  Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades.

Authors:  Yiling Lu; Qinghua Yu; Jue Hui Liu; Jinyi Zhang; Hongwei Wang; Dimpy Koul; John S McMurray; Xianjun Fang; W K Alfred Yung; Kathy A Siminovitch; Gordon B Mills
Journal:  J Biol Chem       Date:  2003-07-17       Impact factor: 5.157

6.  Targeted deletion of PTEN in smooth muscle cells results in vascular remodeling and recruitment of progenitor cells through induction of stromal cell-derived factor-1alpha.

Authors:  Raphael A Nemenoff; Peter A Simpson; Seth B Furgeson; Nihal Kaplan-Albuquerque; Joseph Crossno; Pamela J Garl; James Cooper; Mary C M Weiser-Evans
Journal:  Circ Res       Date:  2008-03-13       Impact factor: 17.367

Review 7.  Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries.

Authors:  A J Turner
Journal:  Biochem Soc Trans       Date:  2003-06       Impact factor: 5.407

8.  Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis.

Authors:  A Horiguchi; D Y T Chen; O B Goodman; R Zheng; R Shen; H Guan; L B Hersh; D M Nanus
Journal:  Prostate Cancer Prostatic Dis       Date:  2007-06-12       Impact factor: 5.554

Review 9.  Inflammation, growth factors, and pulmonary vascular remodeling.

Authors:  Paul M Hassoun; Luc Mouthon; Joan A Barberà; Saadia Eddahibi; Sonia C Flores; Friedrich Grimminger; Peter Lloyd Jones; Michael L Maitland; Evangelos D Michelakis; Nicholas W Morrell; John H Newman; Marlene Rabinovitch; Ralph Schermuly; Kurt R Stenmark; Norbert F Voelkel; Jason X-J Yuan; Marc Humbert
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

10.  Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model.

Authors:  Rachel E Nisbet; Jennifer M Bland; Dean J Kleinhenz; Patrick O Mitchell; Erik R Walp; Roy L Sutliff; C Michael Hart
Journal:  Am J Respir Cell Mol Biol       Date:  2009-06-11       Impact factor: 6.914

View more
  8 in total

1.  Deficiency of Akt1, but not Akt2, attenuates the development of pulmonary hypertension.

Authors:  Haiyang Tang; Jiwang Chen; Dustin R Fraidenburg; Shanshan Song; Justin R Sysol; Abigail R Drennan; Stefan Offermanns; Richard D Ye; Marcelo G Bonini; Richard D Minshall; Joe G N Garcia; Roberto F Machado; Ayako Makino; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-21       Impact factor: 5.464

2.  An Optimized Evans Blue Protocol to Assess Vascular Leak in the Mouse.

Authors:  Marilee J Wick; Julie W Harral; Zoe L Loomis; Edward C Dempsey
Journal:  J Vis Exp       Date:  2018-09-12       Impact factor: 1.355

3.  Protection against vascular leak in neprilysin transgenic mice with complex overexpression pattern.

Authors:  Marilee J Wick; Zoe L Loomis; Julie W Harral; Mysan Le; Carol A Wehling; York E Miller; Edward C Dempsey
Journal:  Transgenic Res       Date:  2016-07-01       Impact factor: 2.788

4.  Sustained Activation of Rho GTPases Promotes a Synthetic Pulmonary Artery Smooth Muscle Cell Phenotype in Neprilysin Null Mice.

Authors:  Vijaya Karoor; Mehdi A Fini; Zoe Loomis; Timothy Sullivan; Louis B Hersh; Evgenia Gerasimovskaya; David Irwin; Edward C Dempsey
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-30       Impact factor: 8.311

Review 5.  Control of vascular smooth muscle function by Src-family kinases and reactive oxygen species in health and disease.

Authors:  Charles E MacKay; Greg A Knock
Journal:  J Physiol       Date:  2014-12-01       Impact factor: 5.182

6.  Effects of Angiotensin II Type 1A Receptor on ACE2, Neprilysin and KIM-1 in Two Kidney One Clip (2K1C) Model of Renovascular Hypertension.

Authors:  Laale F Alawi; Sanjeev Dhakal; Sana E Emberesh; Harshal Sawant; Anhar Hosawi; Unmesha Thanekar; Nadja Grobe; Khalid M Elased
Journal:  Front Pharmacol       Date:  2021-01-29       Impact factor: 5.810

Review 7.  Chronic Obstructive Pulmonary Disease and the Cardiovascular System: Vascular Repair and Regeneration as a Therapeutic Target.

Authors:  Srikanth Karnati; Michael Seimetz; Florian Kleefeldt; Avinash Sonawane; Thati Madhusudhan; Akash Bachhuka; Djuro Kosanovic; Norbert Weissmann; Karsten Krüger; Süleyman Ergün
Journal:  Front Cardiovasc Med       Date:  2021-04-12

Review 8.  Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension.

Authors:  Anastasia Gorelova; Mariah Berman; Imad Al Ghouleh
Journal:  Antioxid Redox Signal       Date:  2021-04-20       Impact factor: 8.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.